This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Distributed Bio, Inc.
Distributed Bio, Inc., headquartered in the United States, is a pioneering biotechnology firm specialising in the development of advanced therapeutic antibodies. Founded in 2012, the company has made significant strides in the biopharmaceutical industry, focusing on innovative solutions for infectious diseases and cancer treatment. With a robust portfolio of proprietary technologies, Distributed Bio offers unique services in antibody discovery and optimisation, leveraging its state-of-the-art platforms to enhance therapeutic efficacy. The company has established a strong market position, recognised for its contributions to the field and collaborations with leading pharmaceutical partners. As a key player in the biotechnology landscape, Distributed Bio continues to push the boundaries of antibody engineering, aiming to deliver transformative therapies that address unmet medical needs.
DitchCarbon Score
How does Distributed Bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Distributed Bio, Inc.'s score of 42 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Distributed Bio, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Charles River Laboratories International, Inc., which may influence its climate commitments and reporting practices. As part of its corporate family, Distributed Bio, Inc. aligns with the sustainability initiatives and climate strategies set forth by Charles River Laboratories. This includes participation in various climate-related initiatives such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 commitment to renewable energy. However, specific reduction targets or achievements for Distributed Bio, Inc. have not been disclosed. In summary, while there is no direct emissions data available for Distributed Bio, Inc., its climate commitments are likely informed by the broader sustainability framework established by its parent company, Charles River Laboratories International, Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,284,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 79,271,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Distributed Bio, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
